Does the media refer more to SGMO or INO?

In the previous week, Sangamo Therapeutics and Sangamo Therapeutics both had 2 articles in the media. Sangamo Therapeutics' average media sentiment score of 0.00 beat Inovio Pharmaceuticals' score of -0.04 indicating that Sangamo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inovio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to FHTX or SGMO?

In the previous week, Foghorn Therapeutics had 4 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 6 mentions for Foghorn Therapeutics and 2 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.00 beat Foghorn Therapeutics' score of -0.19 indicating that Sangamo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SGMO or CBUS more profitable?

Sangamo Therapeutics has a net margin of -310.81% compared to Cibus' net margin of -2,258.89%. Cibus' return on equity of -287.03% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics -310.81% -2,662.06% -132.12% Cibus -2,258.89% -287.03% -27.99%

Does the media favor SGMO or CBUS?

In the previous week, Sangamo Therapeutics and Sangamo Therapeutics both had 2 articles in the media. Cibus' average media sentiment score of 1.82 beat Sangamo Therapeutics' score of 0.00 indicating that Cibus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cibus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer COYA or SGMO?

In the previous week, Coya Therapeutics had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 5 mentions for Coya Therapeutics and 2 mentions for Sangamo Therapeutics. Coya Therapeutics' average media sentiment score of 0.40 beat Sangamo Therapeutics' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ENGN or SGMO more profitable?

enGene has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. enGene's return on equity of -55.79% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -55.79% -45.17% Sangamo Therapeutics -310.81% -2,662.06% -132.12%

Does the media refer more to ENGN or SGMO?

In the previous week, enGene had 23 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 25 mentions for enGene and 2 mentions for Sangamo Therapeutics. enGene's average media sentiment score of 0.17 beat Sangamo Therapeutics' score of 0.00 indicating that enGene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 1 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Sangamo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sangamo Therapeutics (SGMO) Competitors

$0.07 0.00 (0.00%)

As of 10/16/2026

Compare

SGMO vs. INO, FHTX, CBUS, COYA, and ENGN

Should you buy Sangamo Therapeutics stock or one of its competitors? Sangamo Therapeutics's main competitors and comparable companies include Inovio Pharmaceuticals (INO), Foghorn Therapeutics (FHTX), Cibus (CBUS), Coya Therapeutics (COYA), and enGene (ENGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sangamo Therapeutics compare to Inovio Pharmaceuticals?

Sangamo Therapeutics (NASDAQ:SGMO) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Sangamo Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 7,332.43%. Inovio Pharmaceuticals has a consensus price target of $3.17, indicating a potential upside of 219.83%. Given Sangamo Therapeutics' higher possible upside, research analysts clearly believe Sangamo Therapeutics is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Inovio Pharmaceuticals has lower revenue, but higher earnings than Sangamo Therapeutics. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Inovio Pharmaceuticals	$60K	1,706.27	-$84.95M	-$0.91	N/A

In the previous week, Sangamo Therapeutics and Sangamo Therapeutics both had 2 articles in the media. Sangamo Therapeutics' average media sentiment score of 0.00 beat Inovio Pharmaceuticals' score of -0.04 indicating that Sangamo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inovio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Inovio Pharmaceuticals has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Inovio Pharmaceuticals' return on equity of -669.94% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

Summary

Inovio Pharmaceuticals beats Sangamo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Foghorn Therapeutics has a net margin of -175.78% compared to Sangamo Therapeutics' net margin of -310.81%. Foghorn Therapeutics' return on equity of 0.00% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-175.78%	N/A	-31.17%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Foghorn Therapeutics currently has a consensus target price of $6.14, suggesting a potential upside of 232.05%. Sangamo Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Foghorn Therapeutics has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Foghorn Therapeutics has higher earnings, but lower revenue than Sangamo Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	3.55	-$74.28M	-$0.98	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

In the previous week, Foghorn Therapeutics had 4 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 6 mentions for Foghorn Therapeutics and 2 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.00 beat Foghorn Therapeutics' score of -0.19 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Foghorn Therapeutics beats Sangamo Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Cibus?

Sangamo Therapeutics (NASDAQ:SGMO) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 33.8% of Cibus shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 29.9% of Cibus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sangamo Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Cibus has a consensus target price of $9.00, suggesting a potential upside of 581.82%. Given Sangamo Therapeutics' higher probable upside, equities research analysts plainly believe Sangamo Therapeutics is more favorable than Cibus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sangamo Therapeutics and Sangamo Therapeutics both had 2 articles in the media. Cibus' average media sentiment score of 1.82 beat Sangamo Therapeutics' score of 0.00 indicating that Cibus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cibus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Sangamo Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Cibus has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Sangamo Therapeutics has a net margin of -310.81% compared to Cibus' net margin of -2,258.89%. Cibus' return on equity of -287.03% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Cibus	-2,258.89%	-287.03%	-27.99%

Sangamo Therapeutics has higher revenue and earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Cibus	$3.64M	27.72	-$127.08M	-$1.65	N/A

Summary

Sangamo Therapeutics and Cibus tied by winning 7 of the 14 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Coya Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

In the previous week, Coya Therapeutics had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 5 mentions for Coya Therapeutics and 2 mentions for Sangamo Therapeutics. Coya Therapeutics' average media sentiment score of 0.40 beat Sangamo Therapeutics' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coya Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 260.78%. Sangamo Therapeutics has a consensus price target of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Coya Therapeutics has a net margin of -270.22% compared to Sangamo Therapeutics' net margin of -310.81%. Coya Therapeutics' return on equity of -52.05% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Coya Therapeutics has higher earnings, but lower revenue than Sangamo Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	12.54	-$21.23M	-$1.07	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

Summary

Coya Therapeutics beats Sangamo Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Sangamo Therapeutics compare to enGene?

enGene (NASDAQ:ENGN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

enGene has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. enGene's return on equity of -55.79% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.79%	-45.17%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

enGene presently has a consensus price target of $11.05, indicating a potential upside of 561.40%. Sangamo Therapeutics has a consensus price target of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.21
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, enGene had 23 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 25 mentions for enGene and 2 mentions for Sangamo Therapeutics. enGene's average media sentiment score of 0.17 beat Sangamo Therapeutics' score of 0.00 indicating that enGene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	1 Very Positive mention(s)	3 Positive mention(s)	15 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sangamo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.2% of enGene shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

enGene has a beta of -0.29, suggesting that its stock price is 129% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

enGene has higher earnings, but lower revenue than Sangamo Therapeutics. enGene is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$1.13	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

Summary

enGene beats Sangamo Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Sangamo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMO vs. The Competition

Export

Metric	Sangamo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$30.66M	$3.95B	$7.45B	$12.95B
Dividend Yield	N/A	3.64%	2.50%	27.63%
P/E Ratio	-0.17	12.55	275.00	24.84
Price / Sales	0.78	1,175.03	571.54	76.68
Price / Cash	N/A	122.10	76.54	51.88
Price / Book	-1.85	15.94	10.31	5.85
Net Income	-$122.93M	-$22.69M	$3.51B	$381.63M
7 Day Performance	N/A	-8.71%	-5.47%	-5.04%
1 Month Performance	N/A	-15.43%	-9.66%	-7.99%
1 Year Performance	N/A	1.39%	0.73%	-5.68%

Sangamo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMO Sangamo Therapeutics	0.9362 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480
INO Inovio Pharmaceuticals	2.2837 of 5 stars	$1.11 -3.9%	$3.17 +186.6%	-59.8%	$118.91M	N/A	N/A	112
FHTX Foghorn Therapeutics	2.2586 of 5 stars	$1.95 -2.5%	$6.67 +241.9%	-57.1%	$118.77M	$30.91M	N/A	106	Analyst Downgrade Gap Down
CBUS Cibus	1.9736 of 5 stars	$1.48 -4.5%	$9.00 +508.1%	-22.8%	$118.46M	$3.64M	N/A	118	News Coverage Analyst Downgrade
COYA Coya Therapeutics	2.3568 of 5 stars	$4.81 -2.8%	$15.33 +218.8%	-32.5%	$116.12M	$8.02M	N/A	8	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMO) was last updated on 10/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. INO, FHTX, CBUS, COYA, and ENGN

How does Sangamo Therapeutics compare to Inovio Pharmaceuticals?

Summary

How does Sangamo Therapeutics compare to Foghorn Therapeutics?

Summary

How does Sangamo Therapeutics compare to Cibus?

Summary

How does Sangamo Therapeutics compare to Coya Therapeutics?

Summary

How does Sangamo Therapeutics compare to enGene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. INO, FHTX, CBUS, COYA, and ENGN

How does Sangamo Therapeutics compare to Inovio Pharmaceuticals?

Do analysts recommend SGMO or INO?

Which has stronger earnings & valuation, SGMO or INO?

Does the media refer more to SGMO or INO?

Do institutionals & insiders hold more shares of SGMO or INO?

Is SGMO or INO more profitable?

Which has more volatility and risk, SGMO or INO?

Summary

How does Sangamo Therapeutics compare to Foghorn Therapeutics?

Do insiders & institutionals have more ownership in FHTX or SGMO?

Is FHTX or SGMO more profitable?

Do analysts recommend FHTX or SGMO?

Which has more volatility and risk, FHTX or SGMO?

Which has better earnings and valuation, FHTX or SGMO?

Does the media refer more to FHTX or SGMO?

Summary

How does Sangamo Therapeutics compare to Cibus?

Do insiders and institutionals have more ownership in SGMO or CBUS?

Do analysts prefer SGMO or CBUS?

Does the media favor SGMO or CBUS?

Which has more risk and volatility, SGMO or CBUS?

Is SGMO or CBUS more profitable?

Which has better valuation & earnings, SGMO or CBUS?

Summary

How does Sangamo Therapeutics compare to Coya Therapeutics?

Do insiders & institutionals hold more shares of COYA or SGMO?

Which has more volatility and risk, COYA or SGMO?

Does the media prefer COYA or SGMO?

Do analysts prefer COYA or SGMO?

Is COYA or SGMO more profitable?

Which has preferable valuation and earnings, COYA or SGMO?

Summary

How does Sangamo Therapeutics compare to enGene?

Is ENGN or SGMO more profitable?

Do analysts rate ENGN or SGMO?

Does the media refer more to ENGN or SGMO?

Do institutionals and insiders believe in ENGN or SGMO?

Which has more risk and volatility, ENGN or SGMO?

Which has preferable valuation and earnings, ENGN or SGMO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools